A Phase 1, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant (Test vs. Reference) Following Intramuscular Administration to the Gluteal Muscle in Healthy Female Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2018
Price : $35 *
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors Eagle Pharmaceuticals
- 10 May 2018 According to an Eagle Pharmaceuticals media release, enrollment was completed in February 2018 with study results anticipated in the fall of 2018.
- 10 May 2018 Status changed from recruiting to active, no longer recruiting, as reported in Eagle Pharmaceuticals media release
- 26 Feb 2018 According to an Eagle Pharmaceuticals media release, randomization has now been completed ahead of schedule with 600 subjects.